A Study to Evaluate the Safety & Efficacy of ly011 Cell Injection in

Updated 06/21/2024

Status Recruiting

Clinical Trial Summary

Objective to evaluate the safety and efficacy of ly011 cell injection in the treatment of advanced gastric adenocarcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04977193
Study type	Interventional
Source	Shanghai Longyao Biotechnology Inc., Ltd.
Contact
Status	Recruiting
Phase	Early Phase 1
Start date	November 1, 2021
Completion date	November 1, 2024

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04993378` - Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy
	Recruiting	`NCT05583383` - A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab	N/A
	Completed	`NCT06238752` - First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC	Phase 2
	Recruiting	`NCT04209686` - Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma	Phase 2
	Recruiting	`NCT02240524` - Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer	Phase 3
	Completed	`NCT02447380` - Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment	Phase 2
	Recruiting	`NCT06203600` - Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	Phase 2/Phase 3
	Recruiting	`NCT05677490` - mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma	Phase 3
	Completed	`NCT02448329` - Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	Phase 2
	Completed	`NCT02615730` - PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma	Phase 1/Phase 2
	Recruiting	`NCT05041153` - Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	Early Phase 1
	Terminated	`NCT02449655` - Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy	Phase 2
	Completed	`NCT02449551` - Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment	Phase 2
	Not yet recruiting	`NCT04174339` - PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer	N/A
	Completed	`NCT02599324` - Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors	Phase 1/Phase 2
	Recruiting	`NCT06028737` - Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer	Phase 2/Phase 3
	Recruiting	`NCT04675866` - Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer	N/A
	Completed	`NCT02447406` - Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment	Phase 1/Phase 2
	Recruiting	`NCT03159819` - Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma	N/A